Basal cell carcinoma - Carcinoma Cille Basal
☆ AI Dermatology — Free Service
I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
Is minic a dhéantar le leasachán ulcerated a dhéanann difear do chraiceann na srón i duine scothaosta a diagnóisíodh mar Carcinoma Cille Basal (Basal cell carcinoma). Is suíomh coitianta é an srón don chineál seo ailse chraicinn.
D’fhéadfadh go mbeadh teorainneacha neamhrialta agus othair i láthair ag Carcinoma Cille Basal (Basal cell carcinoma).
Is féidir contrártha a dhéanamh ar Carcinoma Cille Basal (Basal cell carcinoma) mar wairte.
relevance score : -100.0%
ReferencesIs é Basal cell carcinoma (BCC) an cineál ailse craicinn is coitianta. Is é nochtadh don sholas na gréine an chúis is mó. Léiríonn beagnach gach cás BCC comharthaíocht róghníomhach Gráinneog san anailís mhóilíneach. Cuirtear cóireálacha éagsúla ar fáil agus roghnaítear iad bunaithe ar riosca atarlaithe, tábhacht caomhnú fíocháin, rogha an othair, agus méid an ghalair.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Is iad Basal cell carcinomas an cineál ailse craicinn is coitianta i measc daoine fásta cothrom-craiceann a bhfuil 50 bliain d'aois agus os a chionn. Tá a líonra ag méadú ar fud an domhain, go príomha mar gheall ar nochtadh don ghrian. Is féidir le coinníollacha géiniteacha áirithe daoine a chur i mbaol na hailse seo a fhorbairt ag aois níos óige. Tá Basal cell carcinomas éagsúil ó thaobh déine, ó loit dromchla nó nodúlach, agus is furasta a chóireáil i gcásanna le breis féidearthachtaí, ach i gcásanna níos fairsinge teastaíonn plé leo i bhfoirne leighis speisialaithe. Braitheann an tuar ar an dóchúlacht go dtiocfaidh an ailse ar ais, nó ar a chumas damáiste a dhéanamh do fhíocháin i ngar don láimhe. Is í máinliacht an chóireáil chaighdeánach don chuid is mó de na cásanna, rud a chinntíonn baint chruinn agus seans íseal go dtarlóidh sé arís. Is féidir le modhanna níos lú ionsaithe déileáil go héifeachtach le loit superficial.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Is é máinliacht an phríomhchóireáil do BCC. I gcás BCC ard‑riosca nó athfhillteach, go háirithe i réimsí ríthábhachtacha, moltar máinliacht faoi rialú micreagrafach. D’fhéadfadh othair a bhfuil BCC superficial íseal‑riosca acu cóireálacha tráthúla nó modhanna millteach a mheas. Oibríonn teiripe fhótadinimiciúil go maith le haghaidh BCCanna nodúlach dromchla agus riosca íseal. Le haghaidh BCC atá chun cinn go háitiúil nó metastatach, moltar coscairí Gráinneog (vismodegib, sonidegib). Má tá dul chun cinn galair nó éadulaingt ar choscóirí Gráinneog, is féidir imdhíonta‑teiripe le anti‑PD1 antibody (cemiplimab) a chur san áireamh. Is rogha mhaith é radaiteiripe d'othair nach féidir leo máinliacht a fháil, go háirithe othair níos sine. D’fhéadfaí leiccheimiteiripe a mheas mura rogha é máinliacht nó radaiteiripe.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
I measc na bhfachtóirí riosca tá nochtadh do sholas ultraíveach, teiripe radaíochta, nochtadh fadtéarmach d’arsanaic, agus drochfheidhm an chórais imdhíonachta (m.sh. trasphlandú orgáin). Tá nochtadh do sholas UV le linn óige thar a bheith díobhálach.
Tar éis diagnóis a dhéanamh le bithóipse, déantar cóireáil de ghnáth trí bhaint máinliachta. Is féidir é seo a dhéanamh go simplí má tá an ailse beag; mura bhfuil an ailse beag, moltar máinliacht Mohs go ginearálta.
Is ionann Carcinoma Cille Basal (Basal cell carcinoma) agus 32 % ar a laghad de gach ailse ar fud an domhain. I measc ailsí craicinn, seachas meileanóma, tá ailsí bunchealla thart ar 80 %. Sna Stáit Aontaithe, tá carcinoma cille basal i gceann 35 % d'fhir bhána agus 25 % de mhná bhána i rith a saol.
○ Diagnóis agus Cóireáil
#Dermoscopy
#Skin biopsy
#Mohs surgery